Jul. 4 at 7:38 AM
$PDSB some points from Frank from this presentation
1-Our phase 3 trial in recurrent metastatic head and neck cancer is underway, targeting the most prevalent and fastest-growing subtype. We’ll provide updates as enrollment progresses and share interim data readouts when we have them.
2- For our prostate and colorectal cancer programs at NCI, we expect the principal investigators to present at major conferences in the near future — we’ll announce where and when.
3- Likewise, we’ll share final updates from our phase 2 head and neck cancer trial and the MD Anderson cervical cancer study soon.
🎯 We truly believe our next-generation cancer vaccine technology can overcome the hurdles that have limited CAR-T and first-generation cancer vaccines. The consistent data we’ve generated so far make us optimistic about the potential across multiple tumor types — not just head and neck and HPV-driven cancers, but many more.
